Impact of Hereditary Angioedema (HAE) Attacks on Quality of Life and Activities of Daily LivingBusse PJ, Caballero T, van Kooten S, Danese S, Goga L
ACAAI 2022
Real-World Treatment Burden Associated with Parenteral On-Demand Therapies for Hereditary AngioedemaTachdjian R, Savic S, Fridman M, Frade J, Audhya PK, Fasehun M
ACAAI 2022
Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On Demand Treatment for Hereditary AngiodemaDavie R, Edwards H, Evans D, Hodgson S, Stocks M, Smith A, Rushbrooke L, Pethen S, Roe M, Clark D, McEwan P, Hampton S
PMID: 36251573
Absorption, metabolism, and excretion of [14C]-sebetralstat (KVD900 following a single oral does in healthy male participantsMutch P, Bashir M, Jung B, Yi P, Iverson M
PMID: 36200371
The Global and Regional Impact of Hereditary Angioedema (HAE) Attacks on Mental Health, Activities of Daily Living and Quality of LifeBusse PJ, Caballero T, van Kooten S, Danese S, Goga L
2022 HAEi Global Leadership Workshop
Patient Perspectives on an Optimal Outcome Measure to Assess Efficacy in the Acute Treatment of Hereditary Angioedema AttacksRiedl MA, Cohn DM, Aygören-Pürsün E, Zanichelli A, Farkas H, Bernstein JA, Lumry WR, Smith MD, Yea CM, Audhya PK
2022 HAEi Global Leadership Workshop
Pharmacology of KVD824, an Investigational Drug for Prophylaxis of HAEGrivcheva-Panovska V, Smith MD, Duckworth EJ, Hampton SL, Yea CM, Mutch P, Iverson M, Hansen E, Feener EP
BRADYKININ SYMPOSIUM
Sebetralstat Effectiveness in the Treatment of Hereditary Angioedema Attacks Rated Mild or Moderate at Baseline in the Phase 2 TrialLonghurst HJ, Smith MD, Yea CM, Audhya PK
ASCIA 2022
Efficacy and Safety of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) in Adolescent and Adult Patients With Hereditary Angioedema: Phase 3 Trial DesignAygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Bernstein JA , Audhya PK, Smith MD, Yea CM, Lumry WR, Riedl MA, Maurer M
EAACI 2022
Novel Oral Small Molecule FXIIa Inhibitor Blocks Contact System Activation In VivoAllen C Clermont, Daniel Lee, Nivetha Murugesan, Hannah J Edwards, Stephen J Pethen, Edward J Duckworth, Sally L Hampton and Edward P Feener
EAACI 2022